Shareholder Alert: The Ademi Firm investigates whether Terns Pharmaceuticals Inc. is obtaining a Fair Price for Public Shareholders

MILWAUKEE, March 25, 2026 /PRNewswire/ -- Ademi LLP is investigating Terns (NASDAQ: TERN) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Merck. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995.